DSM expands industrial biocatalysis platform with c-LEcta agreement
DSM Pharmaceutical Products announced a license agreement with c-LEcta GmbH for proprietary screening technology. The agreement grants DSM rights to c-LEcta’s proprietary alcohol dehydrogenases for enzyme screening programs and development of sustainable manufacturing routes for manufacturing of pharmaceutical active ingredients and intermediates.
Dr. Oliver May, Business Manager for DSM comments: “This agreement further broadens our alcohol dehydrogenase platform which we setup for rapid screening programs for our customers and the development of cost efficient production of a large spectrum of chiral secondary alcohols.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.